279 related articles for article (PubMed ID: 32956836)
21. Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models.
Yang L; Bhattacharya A; Peterson D; Li Y; Liu X; Marangoni E; Robila V; Zhang Y
Drug Resist Updat; 2024 May; 74():101078. PubMed ID: 38503142
[TBL] [Abstract][Full Text] [Related]
22. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
[TBL] [Abstract][Full Text] [Related]
23. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
Zavodovskaya M; Campbell MJ; Maddux BA; Shiry L; Allan G; Hodges L; Kushner P; Kerner JA; Youngren JF; Goldfine ID
J Cell Biochem; 2008 Feb; 103(2):624-35. PubMed ID: 17562544
[TBL] [Abstract][Full Text] [Related]
24. Coamplification of
Floros KV; Lochmann TL; Hu B; Monterrubio C; Hughes MT; Wells JD; Morales CB; Ghotra MS; Costa C; Souers AJ; Boikos SA; Leverson JD; Tan M; Serra V; Koblinski JE; Arribas J; Prat A; Paré L; Miller TW; Dozmorov MG; Harada H; Windle BE; Scaltriti M; Faber AC
Proc Natl Acad Sci U S A; 2018 Mar; 115(11):E2594-E2603. PubMed ID: 29476008
[No Abstract] [Full Text] [Related]
25. A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells.
Giordano CR; Mueller KL; Terlecky LJ; Krentz KA; Bollig-Fischer A; Terlecky SR; Boerner JL
Exp Cell Res; 2012 Oct; 318(16):2014-21. PubMed ID: 22687878
[TBL] [Abstract][Full Text] [Related]
26. Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells.
Kim S; Lee J; Oh SJ; Nam SJ; Lee JE
Oncol Rep; 2015 Sep; 34(3):1613-9. PubMed ID: 26166014
[TBL] [Abstract][Full Text] [Related]
27. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
28. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment.
Weigelt B; Lo AT; Park CC; Gray JW; Bissell MJ
Breast Cancer Res Treat; 2010 Jul; 122(1):35-43. PubMed ID: 19701706
[TBL] [Abstract][Full Text] [Related]
29. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
30. Y-box binding protein-1 contributes to both HER2/ErbB2 expression and lapatinib sensitivity in human gastric cancer cells.
Shibata T; Kan H; Murakami Y; Ureshino H; Watari K; Kawahara A; Kage M; Hattori S; Ono M; Kuwano M
Mol Cancer Ther; 2013 May; 12(5):737-46. PubMed ID: 23445612
[TBL] [Abstract][Full Text] [Related]
31. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
[TBL] [Abstract][Full Text] [Related]
32. Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes.
Watson SS; Dane M; Chin K; Tatarova Z; Liu M; Liby T; Thompson W; Smith R; Nederlof M; Bucher E; Kilburn D; Whitman M; Sudar D; Mills GB; Heiser LM; Jonas O; Gray JW; Korkola JE
Cell Syst; 2018 Mar; 6(3):329-342.e6. PubMed ID: 29550255
[TBL] [Abstract][Full Text] [Related]
33. Transcriptomic and ChIP-sequence interrogation of EGFR signaling in HER2+ breast cancer cells reveals a dynamic chromatin landscape and S100 genes as targets.
Nava M; Dutta P; Zemke NR; Farias-Eisner R; Vadgama JV; Wu Y
BMC Med Genomics; 2019 Feb; 12(1):32. PubMed ID: 30736768
[TBL] [Abstract][Full Text] [Related]
34. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
Yamaoka T; Ohmori T; Ohba M; Arata S; Kishino Y; Murata Y; Kusumoto S; Ishida H; Shirai T; Hirose T; Ohnishi T; Sasaki Y
Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490
[TBL] [Abstract][Full Text] [Related]
35. t-Darpp Promotes Enhanced EGFR Activation and New Drug Synergies in Her2-Positive Breast Cancer Cells.
Denny EC; Kane SE
PLoS One; 2015; 10(6):e0132267. PubMed ID: 26121470
[TBL] [Abstract][Full Text] [Related]
36. Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer.
Sethunath V; Hu H; De Angelis C; Veeraraghavan J; Qin L; Wang N; Simon LM; Wang T; Fu X; Nardone A; Pereira R; Nanda S; Griffith OL; Tsimelzon A; Shaw C; Chamness GC; Reis-Filho JS; Weigelt B; Heiser LM; Hilsenbeck SG; Huang S; Rimawi MF; Gray JW; Osborne CK; Schiff R
Mol Cancer Res; 2019 Nov; 17(11):2318-2330. PubMed ID: 31420371
[TBL] [Abstract][Full Text] [Related]
37. Synergistic Blockade of EGFR and HER2 by New-Generation EGFR Tyrosine Kinase Inhibitor Enhances Radiation Effect in Bladder Cancer Cells.
Tsai YC; Ho PY; Tzen KY; Tuan TF; Liu WL; Cheng AL; Pu YS; Cheng JC
Mol Cancer Ther; 2015 Mar; 14(3):810-20. PubMed ID: 25589492
[TBL] [Abstract][Full Text] [Related]
38. Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine.
Liu Z; Fusi A; Schmittel A; Tinhofer I; Schneider A; Keilholz U
Cancer Biol Ther; 2010 Nov; 10(9):860-4. PubMed ID: 20855957
[TBL] [Abstract][Full Text] [Related]
39. Advances in EGFR/HER2-directed clinical research on breast cancer.
Chow LWC; Lie EF; Toi M
Adv Cancer Res; 2020; 147():375-428. PubMed ID: 32593406
[TBL] [Abstract][Full Text] [Related]
40. SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo.
Pan Y; Xu Y; Feng S; Luo S; Zheng R; Yang J; Wang L; Zhong L; Yang HY; Wang BL; Yu Y; Liu J; Cao Z; Wang X; Ji P; Wang Z; Chen X; Zhang S; Wei YQ; Yang SY
Mol Cancer Ther; 2012 Apr; 11(4):952-62. PubMed ID: 22319204
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]